CN102512387B - Zalcitabine drug composition - Google Patents
Zalcitabine drug composition Download PDFInfo
- Publication number
- CN102512387B CN102512387B CN2011104416188A CN201110441618A CN102512387B CN 102512387 B CN102512387 B CN 102512387B CN 2011104416188 A CN2011104416188 A CN 2011104416188A CN 201110441618 A CN201110441618 A CN 201110441618A CN 102512387 B CN102512387 B CN 102512387B
- Authority
- CN
- China
- Prior art keywords
- zalcitabine
- pharmaceutical composition
- sodium lauryl
- lauryl sulphate
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses a zalcitabine drug composition and a preparation method thereof. The zalcitabine drug composition is characterized in that the drug composition is the zalcitabine tablet, and a weight ratio of the zalcitabine to sodium dodecylsulfate is 100:1. According to the present invention, the duloxetine hydrochloride drug composition has good stability, and provides significant advantages for achievement of purposes of product yield improving, cost reducing, industrialization achieving, and good application in the clinic.
Description
Technical field
The present invention relates to the medicine in field of medicaments, especially relate to a kind of zalcitabine pharmaceutical composition and preparation method thereof.
Background technology
Zalcitabine, have another name called Zalcitabine, is cytosine nucleoside analogs, and the activity of pair HIV-I resisting and HIV-2 is arranged, and comprises the virus to the zidovudine drug resistance.The similar zidovudine of the monocytic effect of Peripheral Blood, but very effective to mononuclear cell and static cell.After absorption, through the deoxycytidine kinase effect, be converted into the monophosphate zalcitabine in cell, under the effect of other cellular enzymes, further be metabolized to the two deoxidation cytidines (ddCTP) of activated triphosphoric acid, suppress competitively hiv reverse transcriptase, thereby stop the extension of viral DNA, self change triphosphoric acid deoxidation cytidine (dCTP) into.The two deoxidation cytidines (ddCTP) of triphosphoric acid are also cell DNA polymerase inhibitor.The t1/2 of ddCTP in cell is about 2～3h.Oral administration biaavailability is about 80%.Obtain the peak plasma drug level and be 0.02～0.04 μ g/m1 take after the oral dose of 0.03mg/kg.Drug level in cerebrospinal fluid is about 15%～20% of plasma concentration.After quiet notes approximately 75% with prototype through renal excretion.In blood plasma, t1/2 is 1～3h, and the patient of renal insufficiency extends.
In Austrian Initial Public Offering, be the 3rd hiv reverse transcriptase inhibitor in April, 1992.Treatment for the aids patient to the zidovudine inefficacy.Or with zidovudine, share treatment HIV in late period and infect (the CD4 counting is less than 200/mm3), clinical demonstration is all got well than alone wherein any curative effect and is not increased the medicine side effect.Common name: zalcitabine;
English name: Zalcitabine;
CAS：7481-89-2；
Chemical name: 2', the 3'-zalcitabine;
Chemical structural formula:
Molecular formula: C9H13N3O3;
Molecular weight: 211.22;
Physicochemical property: white powder.
Pharmacological action: be efabirenz.Chemical composition is ditiocarb sodium, the immunologic function in the time of can strengthening the HIV infection, but current research shows that this medicine of use is without immunoregulation effect.
Indication: this product is mainly used in tolerating acquired immune deficiency syndrome (AIDS) and AIDS related syndromes (ARC) patient of AZT treatment, after this product treatment, can reduce blood-serum P 24 antigen levels and CD4+ T cell is increased.With AZT, share HIV is had to addition or synergism, and can stop the appearance of multidrug resistant disease strain and reduce toxic reaction.Be applicable to be grown up and child's acquired immune deficiency syndrome (AIDS) and AIDS related complex.FDA (food and drug administration) approval and zidovudine share≤300 cubic millimeters for the treatment of adult cd4 cell countings, the hiv infected patient that clinical or the immunology situation worsens.
Application number be CN200610200173.3 disclosure of the invention a kind of anti-cancer medicine sustained-release injection by sustained-release micro-spheres and solvent, formed.Wherein sustained-release micro-spheres comprises anticancer effective component and slow-release auxiliary material, and solvent is the special solvent that contains suspending agent.Antitumor antibiotic is selected from darubicin, valrubicin, pirarubicin, mitoxantrone etc., antimetabolitas be selected from his shore of pemetrexed, Rumi Qu Sai, carmofur, ftorafur, zalcitabine, emtricitabine, galocitabine, ibacitabine, ancitabine, decitabine, flurocitabine, enocitabine, imidazoles, capecitabine, gemcitabine, fludarabine, thunder for song account for, Raltitrexed, dexrazoxane, cladribine, 2-Amino-6-methyl-5-(pyridin-4-ylsulfanyl)-3H-quinazolin-4-one, folic acid etc.; Slow-release auxiliary material is selected from EVAc, polifeprosan, decanedioic acid copolymer, lactic acid thing compound etc.; The suspending agent viscosity is 100cp-3000cp (25 ℃ time), is selected from sodium carboxymethyl cellulose etc.Sustained-release micro-spheres also can be made into sustained-release implant, in tumor or all injections of tumor or place the effect that can strengthen chemoradiotherapy.
Application number be CN200610200257.7 disclosure of the invention a kind of slow releasing injection by sustained-release micro-spheres and solvent, formed.Wherein sustained-release micro-spheres comprises anticancer effective component and slow-release auxiliary material, and solvent is the special solvent that contains suspending agent.Anticancer effective component is be selected from the antimetabolite of his shore of zalcitabine, emtricitabine, galocitabine, ibacitabine, ancitabine, decitabine, flurocitabine, enocitabine, imidazoles, capecitabine, gemcitabine, fludarabine or cladribine and/or be selected from steroids anti-cancer drugs and/or the antimetabolite synergist of platinum-like compounds; Slow-release auxiliary material is selected from copolymer, EVAc of bis-fatty acid and decanedioic acid copolymer, poly-(erucic acid dimer-decanedioic acid), poly-(fumaric acid-decanedioic acid), polifeprosan, polylactic acid one or a combination set of; Suspending agent is selected from carboxymethyl cellulose etc., and the viscosity of suspending agent is 80cp-3000cp (20 ℃-30 ℃ time).Sustained-release micro-spheres also can be made into sustained-release implant, in tumor or all injections of tumor or placement, separately or share with non-operative treatment such as Radiotherapy chemotherapy or microwaves.
Application number be CN200810301483.3 disclosure of the invention a kind of anti-cancer medicine sustained-release injection that contains gemcitabine by sustained-release micro-spheres and solvent, formed.Wherein sustained-release micro-spheres comprises anticancer effective component and slow-release auxiliary material, and solvent is the special solvent that contains suspending agent.Anticancer effective component is gemcitabine or is selected from the antimetabolite of his shore of zalcitabine, emtricitabine, galocitabine, ibacitabine, ancitabine, decitabine, flurocitabine, enocitabine, imidazoles, capecitabine, gemcitabine, fludarabine or cladribine and/or is selected from the antimetabolite synergist of phosphoinositide 3-kinase inhibitor, pyrimidine analogue and/or DNA repairase inhibitor; Slow-release auxiliary material polifeprosan, bis-fatty acid and decanedioic acid copolymer, copolymer of poly lactic acid, EVAc etc.; The suspending agent viscosity is 100cp-3000cp (20 ℃-30 ℃ time), is selected from sodium carboxymethyl cellulose etc.Sustained-release micro-spheres also can be made into sustained-release implant, in tumor or all injections of tumor or place the curative effect that this slow releasing agent can strengthen the non-operative treatment such as Radiotherapy chemotherapy.
Application number be CN200810301484.8 disclosure of the invention a kind of anti-cancer medicine sustained-release injection that contains gemcitabine by sustained-release micro-spheres and solvent, formed.Wherein sustained-release micro-spheres comprises anticancer effective component and slow-release auxiliary material, and solvent is the special solvent that contains suspending agent.Anticancer effective component is gemcitabine or is selected from the antimetabolite of his shore of zalcitabine, emtricitabine, galocitabine, ibacitabine, ancitabine, decitabine, flurocitabine, enocitabine, imidazoles, capecitabine, gemcitabine, fludarabine or cladribine and/or is selected from the antimetabolite synergist of phosphoinositide 3-kinase inhibitor, pyrimidine analogue and/or DNA repairase inhibitor; Slow-release auxiliary material polifeprosan, bis-fatty acid and decanedioic acid copolymer, copolymer of poly lactic acid, EVAc etc.; The suspending agent viscosity is 100cp-3000cp (20 ℃-30 ℃ time), is selected from sodium carboxymethyl cellulose etc.Sustained-release micro-spheres also can be made into sustained-release implant, in tumor or all injections of tumor or place the curative effect that this slow releasing agent can strengthen the non-operative treatment such as Radiotherapy chemotherapy.
The inventor, through studying for a long period of time, gropes repeatedly, optimizes preparation process, and a kind of zalcitabine pharmaceutical composition is provided, and improves bioavailability, reduces production costs, easy to implement, can realize industrialization, remarkable in economical benefits.
Summary of the invention
The first purpose of the present invention is to provide a kind of zalcitabine pharmaceutical composition, this zalcitabine pharmaceutical composition good stability, and bioavailability is high, reduces costs, and realizes industrialization, better is applied to clinically, has more obvious advantage.
The second purpose of the present invention is to provide the preparation method of zalcitabine pharmaceutical composition of the present invention, and the method is simple, prepared zalcitabine pharmaceutical composition, and good stability, bioavailability is high.
For realizing the first purpose of the present invention, the present invention adopts following technical scheme:
A kind of zalcitabine pharmaceutical composition, every 1000 described zalcitabine pharmaceutical compositions, its formula consists of:
A kind of zalcitabine pharmaceutical composition, is characterized in that this pharmaceutical composition is the zalcitabine sheet, and every 1000 its formulas consist of:
Zalcitabine 375g
Mannitol 100g
Sodium lauryl sulphate 3.75g
Hydroxypropyl emthylcellulose 40g
8% PVP K30 alcoholic solution is appropriate
Magnesium stearate 5g
Wherein, zalcitabine: sodium lauryl sulphate weight ratio=100:1.
A kind of zalcitabine pharmaceutical composition, is characterized in that this pharmaceutical composition is the zalcitabine sheet, and every 1000 its formulas consist of:
Zalcitabine 750g
Mannitol 50g
Sodium lauryl sulphate 7.5g
Hydroxypropyl emthylcellulose 60g
8% PVP K30 alcoholic solution is appropriate
Magnesium stearate 5g
Wherein, zalcitabine: sodium lauryl sulphate weight ratio=100:1.
Zalcitabine pharmaceutical composition of the present invention adopts following method to prepare:
1) by mannitol, sodium lauryl sulphate, hydroxypropyl emthylcellulose, polyvidone, magnesium stearate, cross 80 mesh sieves, standby;
2) zalcitabine, mannitol, sodium lauryl sulphate hydroxypropyl emthylcellulose are mixed, cross 80 mesh sieves, three times, mix homogeneously,
3) soft material processed: with 8% PVP K30 alcoholic solution by step 2) soft material processed;
4) granulate: adopt oscillating granulator, 16 eye mesh screens are granulated;
5) drying: wet granular is at 55 ± 5 ℃, and airpillow-dry to pellet moisture is less than 3%;
6) total mixed: the magnesium stearate mix homogeneously that granule is added to recipe quantity;
7) control in: detect pellet moisture, mobility and content, related substance;
8) tabletting: according to cubage sheet weight, regulate loading amount, adopt the 12mm punch die, carry out tabletting, obtain.
Traditional zalcitabine pharmaceutical composition, bioavailability is low, and the stripping result is poor, and quality can't guarantee.
In the present invention, in to zalcitabine pharmaceutical composition supplementary material Study on Compatibility process, discovery adds the sodium lauryl sulphate basic auxiliary, can effectively increase the In Vitro Dissolution rate of release of zalcitabine, through the screening of the test recipes of tens of times and the summary of test data, optimized its recipe quantity, not only solved the problem to poor stability, and effectively improve its In Vitro Dissolution rate of release, constant product quality.
In the present invention, according to the clinical usage and dosage of zalcitabine, optimize prescription, select suitable preparation technology, optimum release profiles, make it be applied in clinical both evade discharging in gastric acid destroy active component, this medicine held stationary is discharged, and the clinical practice side effect is little.
The inventor finds through a large amount of experimental study, when the zalcitabine pharmaceutical composition is above-mentioned formula, and described pharmaceutical composition the best in quality, stability is best.
Another aspect of the present invention provides the preparation method of zalcitabine pharmaceutical composition of the present invention, and the method is simple, prepared zalcitabine pharmaceutical composition good stability, and bioavailability is high.
Preparation method provided by the present invention comprises:
1) by mannitol, sodium lauryl sulphate, hydroxypropyl emthylcellulose, polyvidone, magnesium stearate, cross 80 mesh sieves, standby;
2) zalcitabine, mannitol, sodium lauryl sulphate hydroxypropyl emthylcellulose are mixed, cross 80 mesh sieves, three times, mix homogeneously,
3) soft material processed: with 8% PVP K30 alcoholic solution by step 2) soft material processed;
4) granulate: adopt oscillating granulator, 16 eye mesh screens are granulated;
5) drying: wet granular is at 55 ± 5 ℃, and airpillow-dry to pellet moisture is less than 3%;
6) total mixed: the magnesium stearate mix homogeneously that granule is added to recipe quantity;
7) control in: detect pellet moisture, mobility and content, related substance;
8) tabletting: according to cubage sheet weight, regulate loading amount, adopt the 12mm punch die, carry out tabletting, obtain.
The zalcitabine pharmaceutical composition made according to the inventive method, through industrial amplification production and study on the stability, proves that product is stable, through pharmacology, toxicological test, to human body without injury.
Below by test data, beneficial effect of the present invention is described.
With the product of the embodiment of the present invention 1 and prior art comparative example 3 product, compare stability test, result is as follows:
Embodiment 1 accelerated test result
Comparative example's 4 accelerated test results
Upper table demonstration, the sample comparison of the embodiment of the present invention 1 is more stable from the prescription analysis angle than the sample of embodiment 1; From on Mechanism of Drug Release, embodiment 1 more is better than comparative example 1, can long-acting lasting release, and the release amount is stable, reduces medicining times, has greatly improved the compliance of clinical application.
The invention has the advantages that, overcome problem in prior art, product can be maintained a long-term stability.
Compared with prior art, the present invention has following advantage:
1) the new zalcitabine compositions provided by the present invention dissolution that thoroughly solved zalcitabine is low, the problem of poor stability.
2) zalcitabine pharmaceutical composition provided by the present invention is for the market risk of the yield that improves this product, reduction product, and better being applied to clinical treatment has very large help.
3) new zalcitabine compositions provided by the present invention, through industrialized great production and study on the stability, proves constant product quality, through pharmacology, toxicological test, to human body without injury.
4) preparation method of new zalcitabine compositions provided by the present invention, the method is simple, prepared zalcitabine pharmaceutical composition good stability, bioavailability is high.
The specific embodiment
Below in conjunction with embodiment, the present invention is described in further detail
Embodiment 1
Every 1000 described zalcitabine pharmaceutical compositions, its formula consists of:
Zalcitabine 375g
Mannitol 100g
Sodium lauryl sulphate 3.75g
Hydroxypropyl emthylcellulose 40g
8% PVP K30 alcoholic solution is appropriate
Magnesium stearate 5g
Wherein, zalcitabine: sodium lauryl sulphate weight ratio=100:1.
Preparation technology:
1) by mannitol, sodium lauryl sulphate, hydroxypropyl emthylcellulose, polyvidone, magnesium stearate, cross 80 mesh sieves, standby;
2) zalcitabine, mannitol, sodium lauryl sulphate hydroxypropyl emthylcellulose are mixed, cross 80 mesh sieves, three times, mix homogeneously,
3) soft material processed: with 8% PVP K30 alcoholic solution by step 2) soft material processed;
4) granulate: adopt oscillating granulator, 16 eye mesh screens are granulated;
5) drying: wet granular is at 55 ± 5 ℃, and airpillow-dry to pellet moisture is less than 3%;
6) total mixed: the magnesium stearate mix homogeneously that granule is added to recipe quantity;
7) control in: detect pellet moisture, mobility and content, related substance;
8) tabletting: according to cubage sheet weight, regulate loading amount, adopt the 12mm punch die, carry out tabletting, obtain.
Embodiment 2
Every 1000 described zalcitabine pharmaceutical compositions, its formula consists of:
Zalcitabine 750g
Mannitol 50g
Sodium lauryl sulphate 7.5g
Hydroxypropyl emthylcellulose 60g
8% PVP K30 alcoholic solution is appropriate
Magnesium stearate 5g.
Wherein, zalcitabine: sodium lauryl sulphate weight ratio=100:1.
Preparation technology: with embodiment 1.
The comparative example 1
Every 1000 described zalcitabine pharmaceutical compositions, its formula consists of:
Zalcitabine 375g
Mannitol 100g
Hydroxypropyl emthylcellulose 40g
8% PVP K30 alcoholic solution is appropriate
Magnesium stearate 5g
Preparation technology: with embodiment 1.
Test example 1
This test example is to investigate the stability of zalcitabine compositions provided by the present invention.
The accelerated test of zalcitabine pharmaceutical composition
Method according to the embodiment of the present invention 1 prepares a collection of zalcitabine pharmaceutical composition according to commercially available back, at 40 ℃ ± 2 ℃, the condition of RH75% ± 5% was placed 6 months, during respectively at sampling in the 1st, 2,3,6 months, according to the stability inspection item, detect, and compare with 0 day data.
The accelerated test result
Above conclusion (of pressure testing) can be found out: this product is placed 6 months every detection indexs and with 0 month, is compared no significant difference, good stability under long term test and accelerated test condition.
Claims (3)
1. a zalcitabine pharmaceutical composition, is characterized in that this pharmaceutical composition is the zalcitabine sheet, and every 1000 its formulas consist of:
Wherein, zalcitabine: sodium lauryl sulphate weight ratio=100:1.
2. a zalcitabine pharmaceutical composition, is characterized in that this pharmaceutical composition is the zalcitabine sheet, and every 1000 its formulas consist of:
Wherein, zalcitabine: sodium lauryl sulphate weight ratio=100:1.
3. the preparation method of zalcitabine pharmaceutical composition according to claim 1 and 2, is characterized in that, the method comprises the steps:
1) by mannitol, sodium lauryl sulphate, hydroxypropyl emthylcellulose, polyvidone, magnesium stearate, cross 80 mesh sieves, standby;
2) zalcitabine, mannitol, sodium lauryl sulphate, hydroxypropyl emthylcellulose are mixed, cross 80 mesh sieves, three times, mix homogeneously;
3) soft material processed: with 8% PVP K30 alcoholic solution by step 2) soft material processed;
4) granulate: adopt oscillating granulator, 16 eye mesh screens are granulated;
5) drying: wet granular is at 55 ± 5 ℃, and airpillow-dry to pellet moisture is less than 3%;
6) total mixed: the magnesium stearate mix homogeneously that granule is added to recipe quantity;
7) control in: detect pellet moisture, mobility and content, related substance;
8) tabletting: according to cubage sheet weight, regulate loading amount, adopt the 12mm punch die, carry out tabletting, obtain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104416188A CN102512387B (en) | 2011-12-26 | 2011-12-26 | Zalcitabine drug composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104416188A CN102512387B (en) | 2011-12-26 | 2011-12-26 | Zalcitabine drug composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102512387A CN102512387A (en) | 2012-06-27 |
| CN102512387B true CN102512387B (en) | 2013-11-27 |
Family
ID=46283648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011104416188A Expired - Fee Related CN102512387B (en) | 2011-12-26 | 2011-12-26 | Zalcitabine drug composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102512387B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103768029B (en) * | 2012-10-19 | 2017-01-11 | 安徽贝克生物制药有限公司 | High stability lafutidine tablets and preparation process thereof |
| CN104069126A (en) * | 2014-07-02 | 2014-10-01 | 浙江康乐药业股份有限公司 | Medicine for treating hyperacidity and preparation method thereof |
| CN112220771B (en) * | 2020-11-10 | 2023-03-31 | 成都大学 | Zalcitabine osmotic pump type controlled release tablet and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1846672A (en) * | 2006-01-09 | 2006-10-18 | 济南帅华医药科技有限公司 | Anticancer medicine composition containing antimetabolite |
| CN101244036A (en) * | 2008-03-28 | 2008-08-20 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | High dispersion does type containing cholesterol group phosphoryl nucleoside analogue |
| CN101637444A (en) * | 2006-03-17 | 2010-02-03 | 山东蓝金生物工程有限公司 | Anti-cancer drug slow release injection containing gemcitabine |
-
2011
- 2011-12-26 CN CN2011104416188A patent/CN102512387B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1846672A (en) * | 2006-01-09 | 2006-10-18 | 济南帅华医药科技有限公司 | Anticancer medicine composition containing antimetabolite |
| CN101637444A (en) * | 2006-03-17 | 2010-02-03 | 山东蓝金生物工程有限公司 | Anti-cancer drug slow release injection containing gemcitabine |
| CN101244036A (en) * | 2008-03-28 | 2008-08-20 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | High dispersion does type containing cholesterol group phosphoryl nucleoside analogue |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102512387A (en) | 2012-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102657629B (en) | Ticagrelor sustained-release tablet system and preparation method thereof | |
| US20170266213A1 (en) | Use of beta-nicotinamide mononucleotide in preparation of anti-aging drugs or health-care products | |
| CN101461790B (en) | Lamivudine tablet and preparation method | |
| CN102512387B (en) | Zalcitabine drug composition | |
| WO2015058664A1 (en) | Use of icariin in preparing medicine for preventing or treating decrease in blood cells | |
| CN101220071B (en) | Stable 6-methoxy-2',3'-dideoxy guanine nucleoside, method for preparing the same and medicament composition containing the same | |
| CN103263433A (en) | Medical application of natural product 6-shogaol in enhancing chemosensitivity of pancreatic cancer on gemcitabine and compound drug composite of natural product 6-shogaol | |
| CN104546823A (en) | Application of anhydroicaritin in preparing drug for treating or preventing thrombopenia | |
| CN102144984B (en) | Easy-dissolution lamivudine tablet and preparation method thereof | |
| WO2006104292A1 (en) | Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts | |
| CN102335429B (en) | Tumor inhibiting medicine composition and purpose thereof | |
| CZ155799A3 (en) | Pharmaceutical preparations containing lamivudin and zidovudin | |
| CN112691107B (en) | Pharmaceutical composition and application thereof | |
| CN103860511B (en) | A kind of Pharmaceutical composition containing Irbesartan and Amlodipine Besylate Tablet and preparation method thereof | |
| CN103169728A (en) | Anti-AIDS (Acquired Immune Deficiency Syndrome) compound preparation and preparation method thereof | |
| CN102370983B (en) | Anti-tumor medicine composition and purpose thereof | |
| CN103908465B (en) | A kind of two husband's stators of neat Duola's rice that are easy to stripping and preparation method thereof | |
| CN103083339B (en) | Adefovir dipivoxil pharmaceutical composition | |
| CN101732316A (en) | Lamivudine preparation and preparation method thereof | |
| CN1923173A (en) | Anti-cancer drugs slow release agent comprising anticancer antibiotics and booster thereof | |
| CN1608623A (en) | Enteric coated donepezil hydrochloride tablet and its perpn process | |
| CN102327220B (en) | Solid loratadine lipidosome preparation | |
| CN114392239B (en) | Compound tablet of lamivudine, zidovudine and efavirenz and preparation method thereof | |
| CN102133203B (en) | Lacidipine dispersible tablet and preparation method thereof | |
| CN101269025A (en) | Famciclovir sustained-release dropping pill and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHANG MIN Free format text: FORMER OWNER: TIANJIN SONGRUI MEDICAL TECHNOLOGY CO.,LTD. Effective date: 20140320 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140320 Address after: 300250 Taixing apartment, Taixing Road, Hedong District, Tianjin, 14-1-102 Patentee after: Zhang Min Address before: 300250 Taixing apartment, Taixing Road, Hedong District, Tianjin, 14-1-102 Patentee before: Tianjin Songrui Medical Technology Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131127 Termination date: 20171226 |